文献速递泌尿生殖与妇科肿瘤放疗

高危局部晚期前列腺癌前列腺与盆腔淋巴结对比单纯前列腺调强放疗的2期随机试验(PIVOTAL)的毒性与患者报告结局

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-12-06

PIVOTAL是一项2期非比较性多中心随机试验,124例高危局部晚期前列腺癌患者随机接受单纯前列腺调强放疗(74 Gy/37次)或前列腺+盆腔淋巴结调强放疗(前列腺74 Gy/37次,盆腔60 Gy/37次)。第18周急性下消化道RTOG≥2级无毒性率在前列腺组为96.7%(90%CI 90.0-99.4),前列腺+盆腔组为95.2%(90%CI 88.0-98.7);2年RTOG≥2级消化道累积毒性分别为16.9%和24.0%。结论认为高剂量盆腔淋巴结调强放疗可在多中心安全实施,副作用谱温和,但对疾病控制的影响尚待确定。

要点

  • 第18周急性下消化道RTOG≥2级无毒性率:单纯前列腺组96.7%(59/61),前列腺+盆腔组95.2%(59/62)。
  • 第6周≥2级毒性发生率:单纯前列腺组7%(4/61),前列腺+盆腔组26%(16/61)。
  • 2年RTOG≥2级消化道累积毒性:单纯前列腺组16.9%,前列腺+盆腔组24.0%;膀胱毒性分别为5.1%和5.6%。

核心结论

  • PIVOTAL显示高剂量盆腔淋巴结调强放疗可在多中心实施,副作用谱温和。
  • 尽管安全性数据令人鼓舞,前列腺+盆腔调强放疗对疾病控制的影响尚待确定。

研究设计与样本

  • 2期非比较性多中心随机试验,2011年5月至2013年3月随机124例高危局部晚期前列腺癌患者(单纯前列腺组62例,前列腺+盆腔组62例)。
  • 单纯前列腺组:前列腺74 Gy/37次;前列腺+盆腔组:前列腺74 Gy/37次,盆腔60 Gy/37次。
  • 主要终点为第18周急性下消化道RTOG毒性,旨在排除前列腺+盆腔组≥2级无毒性率80%;关键次要终点包括患者报告结局和晚期毒性。
  • 中位随访37.6个月(四分位距35.4-38.9个月),中位年龄69岁(四分位距64-74岁),中位诊断时前列腺特异性抗原水平21.6 ng/mL(四分位距11.8-35.1 ng/mL)。

主要发现

  • 第18周≥2级下消化道无毒性率:单纯前列腺组59/61(96.7%;90%CI 90.0-99.4),前列腺+盆腔组59/62(95.2%;90%CI 88.0-98.7)。
  • 两组炎症性肠病问卷症状和Vaizey失禁评分均报告相似且低。
  • 第6周≥2级毒性发生率:单纯前列腺组4/61(7%),前列腺+盆腔组16/61(26%),为组间最大差异。
  • 2年RTOG≥2级消化道累积毒性:单纯前列腺组16.9%(95%CI 8.9%-30.9%),前列腺+盆腔组24.0%(95%CI 8.4%-57.9%)。
  • 2年RTOG≥2级膀胱毒性:单纯前列腺组5.1%(95%CI 1.7%-14.9%),前列腺+盆腔组5.6%(95%CI 1.8%-16.7%)。

临床怎么用

  • 原文结论指出高剂量盆腔淋巴结调强放疗可在多中心实施且副作用谱温和,但未据此给出具体临床推荐。
  • 原文结论指出前列腺+盆腔调强放疗对疾病控制的影响尚待确定。

局限性

  • 原文结论指出前列腺+盆腔调强放疗对疾病控制的影响尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase 2 noncomparative multicenter trial, 124 patients with locally advanced, high-risk prostate cancer were randomized between prostate-only IMRT (PO) (74 Gy/37 fractions) and prostate and pelvic lymph node IMRT (P&P; 74 Gy/37 fractions to prostate, 60 Gy/37 fractions to pelvis). The primary endpoint was acute lower gastrointestinal (GI) Radiation Therapy Oncology Group (RTOG) toxicity at week 18, aiming to exclude a grade 2 or greater (G2+) toxicity-free rate of 80% in the P&P group. Key secondary endpoints included patient-reported outcomes and late toxicity. RESULTS: One hundred twenty-four participants were randomized (62 PO, 62 P&P) from May 2011 to March 2013. Median follow-up was 37.6 months (interquartile range [IQR], 35.4-38.9 months). Participants had a median age of 69 years (IQR, 64-74 years) and median diagnostic prostate-specific androgen level of 21.6 ng/mL (IQR, 11.8-35.1 ng/mL). At week 18, G2+ lower GI toxicity-free rates were 59 of 61 (96.7%; 90% confidence interval [CI], 90.0-99.4) for the PO group and 59 of 62 (95.2%; 90% CI, 88.0-98.7) for the P&P group. Patients in both groups reported similarly low Inflammatory Bowel Disease Questionnaire symptoms and Vaizey incontinence scores. The largest difference occurred at week 6 with 4 of 61 (7%) and 16 of 61 (26%) PO and P&P patients, respectively, experiencing G2+ toxicity. At 2 years, the cumulative proportion of RTOG G2+ GI toxicity was 16.9% (95% CI, 8.9%-30.9%) for the PO group and 24.0% (95% CI, 8.4%-57.9%) for the P&P group; in addition, RTOG G2+ bladder toxicity was 5.1% (95% CI, 1.7%-14.9%) for the PO group and 5.6% (95% CI, 1.8%-16.7%) for the P&P group. CONCLUSIONS: PIVOTAL demonstrated that high-dose pelvic lymph node IMRT can be delivered at multiple centers with a modest side effect profile. Although safety data from the present study are encouraging, the impact of P&P IMRT on disease control remains to be established.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dearnaley D, Griffin CL, Lewis R, et al. Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL). Int J Radiat Oncol Biol Phys. 2018. PMID: 30528653. doi:10.1016/j.ijrobp.2018.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。